Oral Iohexol in the Management of Chylous Ascites After Retroperitoneal or Extended Lymphadenectomy for Abdominal or Pelvic Malignant Tumor: an Innovative and Convenient Treatment

The goal of this clinical trial is to assess the effectiveness of oral iohexol in the treatment of postoperative chylous ascites. It will also learn about the safety of oral iohexol. The main questions it aims to answer are:
* Confirm the potential of oral iohexol as an innovative therapeutic regimen.
* Confirm its ability to improve clinical outcomes for patients.

开始日期2025-02-15

申办/合作机构

中国医学科学院肿瘤医院

NCT06709521

/ Recruiting临床4期IIT

Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

开始日期2025-02-12

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT06259422

/ Not yet recruitingN/A

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

This study is a single centre intervention study to compare two methods of determining the measured glomerular filtration rate (mGFR). Subjects who receive radioactively labeled iothalamate (125I) and hippuran (131I) within the framework of routine clinical care, will be co-administered iohexol. The primary trial endpoint is the mGFR when administered 125I-iothalamate and 131I-hippuran versus iohexol. By determining the mGFR using both iohexol and iothalamate in the same patients, a direct comparison of the two methods can be made in terms of their accuracy and precision. This makes it possible to determine the potential use of the non-radioactive measurement method as an alternative to the radioactive method and thus lower the overall radioactive burden for patients and personnel.

开始日期2024-06-01

申办/合作机构

University Medical Center Groningen

100 项与碘海醇相关的临床结果

登录后查看更多信息

100 项与碘海醇相关的转化医学

登录后查看更多信息

100 项与碘海醇相关的专利（医药）

登录后查看更多信息

3,498

项与碘海醇相关的文献（医药）

2025-12-31·RENAL FAILURE

Dimethyl fumarate ameliorated pyroptosis in contrast-induced acute renal injury by regulating endoplasmic reticulum stress and JAK2-STAT3 pathway

Article

作者: Xu, Youhua ; Guo, Xieyi ; Yin, Min ; An, Xiaoning ; Gui, Dingkun ; Shen, Yilan ; Cheng, Dongsheng

BACKGROUND:

Inflammation and oxidative stress are important pathological processes of contrast-induced acute renal injury (CIAKI). This study explored whether DMF had therapeutic effects and investigated the underlying mechanism in CIAKI.

METHODS:

A CIAKI animal model was established in C57BL/6J mice with iohexol, and DMF was used as an intervention. In vitro, HK-2 cells were treated with iohexol and DMF. RNA-seq analysis was performed on the renal tissue of the mice. Protein-protein interaction (PPI), and enrichment analysis were subsequently conducted. In addition, endoplasmic reticulum stress (ERS) activation and STAT3 inhibition were used to study the relationships among ERS, the JAK2-STAT3 pathway and pyroptosis.

RESULTS:

DMF improved the renal function of CIAKI model mice. Enrichment analysis revealed that the differentially expressed genes (DEGs) were enriched mostly in the acute phase response and the JAK-STAT pathway. The results revealed that inflammation, ERS and pyroptosis increased in the CIAKI group but decreased after DMF treatment. Further study revealed that the JAK2-STAT3 pathway was overactivated in vivo and in vitro and that DMF inhibited the JAK2-STAT3 pathway. In addition, ERS activation could increase the JAK2-STAT3 pathway and pyroptosis, while STAT3 knockdown could reverse pyroptosis, indicating that ERS could activate the JAK2-STAT3 pathway, further triggering pyroptosis. DMF ameliorated pyroptosis through regulating ERS and the JAK2-STAT3 pathway in CIAKI.

CONCLUSION:

This study demonstrated that DMF had renoprotective effects on CIAKI. DMF ameliorated pyroptosis through the inhibition of ERS and the JAK2-STAT3 pathway.

2025-09-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous determination of three iodinated contrast media in human plasma by LC/MS-MS and its clinical application

Article

作者: Wu, Xiaofei ; Wang, Hongyun ; Wang, Yaoyao ; Cai, Jianfang ; Liu, Shupeng

Iodinated contrast media (ICM), including iohexol, iopromide and iodixanol, have significantly enhanced diagnostic accuracy, particularly in cardiovascular and cerebrovascular diseases. The three ICM is tailored to specific patient needs and diagnostic contexts. However, excessive doses of ICM may induce adverse reactions, including nephrotoxicity. Accurate measurement of ICM concentration is essential for reducing renal burden and ensuring patient safety. Current methods for quantifying ICM are often limited to single-analyte detection (especially iohexol), which is inefficient for clinical practice. Therefore, this method aims to develop and validate a rapid, generic LC-MS/MS method for simultaneously quantifying iohexol, iopromide, and iodixanol in human plasma to improve patient management and prognosis. An LC-MS/MS-based approach was established utilizing an C18 column coupled with a Xevo TQ-S triple quadrupole mass spectrometer. Sample preparation involved protein precipitation, while chromatographic separation was achieved using acetonitrile and 0.1 % formic acid in water. The developed LC-MS/MS method achieved satisfactory separation of the three ICM within 1.5 min. Calibration curves for iohexol, iopromide, and iodixanol showed good linearity in 5.00-5000, 5.00-5000 and 10.0 ∼ 10000 µg/mL, respectively. The method was effectively applied to analyze 71 plasma samples from 9 patients, highlighting its clinical utility. A rapid and generic LC-MS/MS method streamlines sample preparation and standardizes laboratory workflows, making it suitable for clinical bio-samples.

2025-07-01·JOURNAL OF HAZARDOUS MATERIALS

Amino-functionalized MIL-101(Fe)-NH2 as efficient peracetic acid activator for selective contaminant degradation: Unraveling the role of electron-donating ligands in Fe(IV) generation

Article

作者: Li, Zongchen ; El-Din, Mohamed Gamal ; Lu, Jian ; Zheng, Zheng-Xiong ; Xu, Bin ; Tang, Yu-Lin ; Hu, Chen-Yan ; Fu, Qi ; Pan, Renjie ; Shi, Jun ; Zhang, Tian-Yang

Peracetic acid-based advanced oxidation processes (PAA-AOPs), which generate various reactive radicals, have garnered substantial attention for degradation emerging contaminants (ECs). However, nonselective radical-based PAA-AOPs often suffer from interference by water matrix components, causing low contaminants removal efficiency. This study explores the use of amino-(NH₂)-functionalized metal-organic frameworks (MIL-101(Fe)-NH₂) as heterogeneous catalysts for PAA activation, enabling the generation of high-valent iron- (Fe)-oxo species (Fe(IV)) capable of efficiently degrading ECs (80 -100 %, within 30 min). The Fe(II) clusters in MIL-101(Fe)-NH₂, modulated by electron-donating -NH₂ groups, play a pivotal role in Fe(IV) generation. Scavenger and probe experiments confirmed Fe(IV) as the primary reactive species responsible for ECs degradation. Density functional theory calculations demonstrated that the four-electron transfer to generate Fe(IV) has lower free energy than the two-electron transfer to generate organic radicals (e.g., CH₃COO^• and CH₃C(O)OO^•). Furthermore, thermodynamically unfavorable CH₃COO^• desorption further promotes Fe(IV) generation. The PAA/MIL-101(Fe)-NH₂ system efficiently degraded SMX (k_app= 121.2 -287.2 M^-1s^-1) and other ECs (k_app= 40 -432 M^-1s^-1) with minimal interference from water matrix components and excellent reusability. This study demonstrates that MIL-101(Fe)-NH₂ is a robust catalyst for PAA activation and provides a novel approach for selectively generating Fe(IV) for ECs degradation.

项与碘海醇相关的新闻（医药）

2025-04-24

·北陆药业

北陆药业2025年一季度业绩开门红收入利润继续增长

近日，北陆药业（300016）发布《2025年第一季度报告》。在2024年度业绩稳定增长的基础上，2025年，北陆药业又迎来一个开门红！2025年第一季度，北陆药业实现营业收入28,268.07万元，同比增长36.23%；实现归属于上市公司股东的净利润1,453.85万元，同比上涨26.13%；归属于上市公司股东的扣除非经常性损益的净利润1,308.80万元，同比上涨14.34%。报告期内，北陆药业业绩增长源于三大核心驱动力的共同发力：1、化学仿制药板块通过精准把握国家集采政策机遇，主力产品在首轮及续标中持续扩大市场份额，销售稳步提升，夯实利润基础盘；2、中成药板块通过并购实现快速整合扩张，产品管线与现有营销网络形成互补优势，成为业绩增长的新动能；3、海外市场拓展成效显现，国际化销售网络建设推动出口业务连续多季度增长。北陆药业将继续落实“化药+中药”双轮驱动战略，同时兼顾国内与海外市场并重，在注重业务稳步发展的同时，通过盈利能力的同步提升，为公司的高质量发展提供强劲支撑。往期推荐01 北陆药业2024年收入稳健增长净利润同比增幅120%！02【喜报】北陆药业碘海醇注射液欧盟获批上市03 北陆药业控股子公司海昌药业碘帕醇化学原料药获批上市识别二维码关注我们

财报

2025-04-17

·北陆药业

北陆药业2024年收入稳健增长净利润同比增幅120%！

近日，北陆药业（300016）发布《2024年年度报告》。2024年度，北陆药业继续稳健经营，实现营业收入98,355.45万元，同比增长10.42%；归属于上市公司股东的净利润1,365.17万元，同比增加119.02%，其中母公司净利润5,635.84万元，同比增加838.39%；归属于上市公司股东的扣除非经常性损益的净利润1,409.44万元，同比增加120.27%。为完成“二次创业”、实现“中国医药制造百强企业”的中长期目标，北陆药业在2024年继续落实“化药+中药”双轮驱动战略布局，主营业务依然专注于对比剂、降糖药以及中枢神经类中成药的生产与销售，同时通过收购承德天原药业进一步扩大中成药战略版图。稳健经营化药板块收入持续增长公司经过近两年的持续改革，逐步克服了化学药主打产品碘对比剂及降糖药管线受集采价格下降带来的巨大挑战，在首次中标执标及后续接续中标工作的推动下，实现了集采产品销量的增长。同时，公司也积极拥抱集采政策，将其作为公司研发、营销等工作的重要考量因素，加大对拟参与集中带量采购产品的研发及申报，力争抓住集采执标的契机，扩大产品的市场份额及品牌影响力。以上举措为公司提供稳定的利润支撑，确保良好的现金流状况，为公司的长期发展奠定坚实的基础。2024年度，公司对比剂产品实现销售收入58,804.95万元，同比增长9.87%，公司降糖类产品实现销售收入12,598.34万元，同比增长33.24%。原料药批文增加持续开拓海外市场原料药是公司化药板块的重要组成部分，北陆药业原料药产品涵盖钆类及碘类的原料药及辅料、中间体等，在保障制剂生产之余，各产品也积极开拓国内及国外市场。控股子公司海昌药业是国内为数不多的具有碘类对比剂原料药生产资质和产能的企业之一，其年产1000吨的碘造影剂项目设有碘海醇、碘克沙醇、碘普罗胺、碘佛醇、碘帕醇、碘比醇及碘美普尔等共计7个品种生产线。除了碘海醇，海昌药业已陆续获批碘克沙醇原料药、碘帕醇原料药等批件，为公司“原料药+制剂”一体化战略进一步夯实基础。同时海昌相关原料药产品也在积极申报海外注册。海昌药业在原料药方面的优势和产业布局的增强，有利于提升公司产品的多样性及公司的综合竞争力。深化中成药战略布局中药收入同比增长19.65%加大中成药板块布局是公司近几年的发展战略之一，公司通过并购中成药企业拓展中成药板块业务，逐步构建丰富的产品矩阵及核心竞争力，努力提升公司的市场份额及影响力，进一步增强公司在中成药领域的品牌形象。九味镇心颗粒是国内第一个通过国家食品药品监督管理总局批准治疗广泛性焦虑症的纯中药制剂，也是公司确立“抗焦虑中药第一品牌”的“黄金单品”。报告期内，公司收购天原药业80%的股权，其拥有的58个中药批文成为公司中成药板块重要组成部分。截至报告期末，天原药业生产、销售的品种共计20种，涵盖清热解毒类、感冒类、补肾强身类、脾胃肠消化类、活血止痛类、肝胆类，其中，核心产品金莲花颗粒系全国独家品种、国家医保乙类、OTC 乙类，系公司全力打造的另一“黄金单品”。公司金莲花颗粒、感冒清热颗粒等中药品种已中标多个地方集采，公司将借助集采执标，协同基层布局，提升金莲花颗粒等产品的市场份额及品牌影响力。报告期内，公司中药制剂实现销售收入16,844.68万元，同比增长19.65%。对比剂全线出海海外收入同比增长15.02%公司海外市场前期的拓展工作成效凸显。公司出口的产品主要为对比剂制剂及原料药，业务覆盖范围为南美洲、非洲、亚洲等市场，公司没有产品出口美国。报告期内，公司对比剂全线产品成功出海并实现营收大幅增长。原料药方面，不仅海昌药业的碘类原料药继续拓展海外市场，沧州分公司生产钆类原料药也逐步实现了国际化。随着欧盟EU GMP认证和巴西ANVISA GMP合规认证的完成，公司对比剂产品的国际化有望进一步提速。九味镇心颗粒在香港和泰国的注册工作继续按计划推进，为出口东南亚等地创造条件。报告期内，公司实现海外营业收入13,216.14万元，同比增长15.02%。储备产品丰富产品梯队建设成型经过2年多的研发投入和收购工作，公司的产品矩阵相对丰富，管线也实现了多元化。报告期内，公司获批钆特酸葡胺制剂及原料药、盐酸帕罗西汀肠溶缓释片、西甲硅油乳剂、复方聚乙二醇电解质散（Ⅲ）、钆布醇注射液新增规格的注册证书，完成了钆喷酸葡胺注射液、钆贝葡胺注射液一致性评价。研发团队不断提升研发效率，为扩大公司在相关领域的战略布局积极储备具有市场竞争潜力的品种。截至目前，公司审评中的项目12项，研发立项项目23项，共计35项。通过并购，公司中药领域批文数量达到59个，其中医保品种45个、基药品种18个、OTC品种41个。九味镇心颗粒、金莲花颗粒、五子衍宗丸、连翘败毒丸、参苓白术丸、消栓通络片、利肝隆片等21个品种在产在销，其余品种皆作为储备品种，等待适当时机开发上市。2025年，公司管理层将在董事会的带领下继续落实各项发展目标。包括但不限于各部门统筹协作，全面落实公司年度目标；加强各生产基地建设及管理，全面提升公司产能；继续推进天原药业的整合与赋能工作，提升中成药业务盈利水平；继续深化营销体系改革，强化营销管理中心职能，狠抓关键政策和重点项目的落地；坚持创新驱动，培养核心团队，提升研发能效；加速公司国际化进程，提升海外市场营收贡献；继续加强内控管理，有效控制风险。关于北陆药业年报更多信息可登录巨潮资讯网www.cninfo.com.cn查询。往期推荐01 【喜报】北陆药业碘海醇注射液欧盟获批上市02北陆药业控股子公司海昌药业碘帕醇化学原料药获批上市03 控股子公司海昌药业碘克沙醇原料药取得韩国注册证书识别二维码关注我们

财报带量采购并购申请上市基因疗法

2025-04-07

·信狐药迅

东阳光英强布韦片掘金7.8亿市场；青峰创新流感药玛舒拉沙韦获批上市| 新获批(3.31-4.6）

每周药品注册获批数据，分门别类呈现，一目了然。(3.31-4.6）新药上市申请药品名称企业注册分类受理号SHR0302片江苏恒瑞医药股份有限公司1CXHS2300108GP681片江西青峰药业有限公司1CXHS2300106英强布韦片宜昌东阳光长江药业股份有限公司1CXHS2300069新药临床申请药品名称企业注册分类受理号INS018_055片英矽智能科技(上海)有限公司1CXHL2500120HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500111HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500110HRS-1167片江苏恒瑞医药股份有限公司1CXHL2500109BIOS-0618片杭州百诚医药科技股份有限公司1CXHL2500104BIOS-0618片杭州百诚医药科技股份有限公司1CXHL2500103TQB3912片正大天晴药业集团股份有限公司1CXHL2500108TQB3912片正大天晴药业集团股份有限公司1CXHL2500107HBW-012336胶囊成都海博为药业有限公司1CXHL2500099HRS-6719片山东盛迪医药有限公司1CXHL2500094HRS-6719片山东盛迪医药有限公司1CXHL2500092GenSci128片长春金赛药业有限责任公司1CXHL2500080IMP1707片上海瑛派药业有限公司1CXHL2500088GenSci128片长春金赛药业有限责任公司1CXHL2500081IMP1707片上海瑛派药业有限公司1CXHL2500089HS-10380片江苏豪森药业集团有限公司1CXHL2401508CMC-2310口溶膜复星医药(徐州)有限公司2.2CXHL2500113CMC-2310口溶膜复星医药(徐州)有限公司2.2CXHL2500112ASKC635干混悬剂江苏奥赛康药业有限公司2.2CXHL2500083HZ039干混悬剂浙江和泽医药科技股份有限公司2.2CXHL2500029HZ039干混悬剂浙江和泽医药科技股份有限公司2.2CXHL2500028注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500118HK241雾化吸入溶液南京华盖制药有限公司2.4CXHL2500106三价流感病毒裂解疫苗(ZFA02佐剂)安徽智飞龙科马生物制药有限公司1.3CXSL2500007PT217凡恩世制药(北京)有限公司1CXSL2500090注射用DR30206浙江道尔生物科技有限公司1CXSL2500079BNT324映恩生物制药(苏州)有限公司1CXSL2500073BNT327百欧恩泰(上海)医药有限公司1CXSL2500072注射用TQB2922正大天晴药业集团南京顺欣制药有限公司1CXSL2500062注射用7MW3711迈威(上海)生物科技股份有限公司1CXSL2500057注射用ZL-1310再鼎医药(上海)有限公司1CXSL2500052SSGJ-627注射液三生国健药业(上海)股份有限公司1CXSL2500024ZT006片北京质肽生物医药科技有限公司1CXSL2500021ZT006片北京质肽生物医药科技有限公司1CXSL2500020ZT006片北京质肽生物医药科技有限公司1CXSL2500019泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2500014DJ-01注射剂苏州德进生物制药有限公司2.4CXSL2500059仿制药申请药品名称企业注册分类受理号腺苷钴胺胶囊四川新斯顿制药股份有限公司3CYHS2302959吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302936吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302935吡拉西坦注射液石家庄凯达生物工程有限公司3CYHS2302934氨茶碱注射液浙江北生药业汉生制药有限公司3CYHS2302798碳酸氢钠林格注射液河北天成药业股份有限公司3CYHS2302620甲硫酸新斯的明注射液上海旭东海普药业有限公司3CYHS2302585甲硫酸新斯的明注射液上海旭东海普药业有限公司3CYHS2302584奥美拉唑碳酸氢钠胶囊(II)宁波美诺华天康药业有限公司3CYHS2302576奥美拉唑碳酸氢钠胶囊宁波美诺华天康药业有限公司3CYHS2302575盐酸多巴胺注射液遂成药业股份有限公司3CYHS2302519盐酸多巴胺注射液遂成药业股份有限公司3CYHS2302518依帕司他片河北瑞森药业有限公司3CYHS2302427布美他尼注射液四川美大康华康药业有限公司3CYHS2302402重酒石酸间羟胺注射液安徽美来药业股份有限公司3CYHS2302378脑脊髓手术用灌流液山东齐都药业有限公司3CYHS2302269氯化钾注射液南京赛瑞谱顿制药有限公司3CYHS2302235碳酸氢钠注射液石家庄四药有限公司3CYHS2302249福多司坦口服溶液江苏联环药业股份有限公司3CYHS2302224氯化钾注射液海南景泽康生物科技有限公司3CYHS2302201硫辛酸片湖南先施制药有限公司3CYHS2302036硫辛酸片湖南先施制药有限公司3CYHS2302035泊马度胺胶囊扬子江药业集团有限公司3CYHS2301871泊马度胺胶囊扬子江药业集团有限公司3CYHS2301870米诺地尔搽剂山东百诺医药股份有限公司3CYHS2301792左乙拉西坦缓释片东北制药集团沈阳第一制药有限公司3CYHS2301768己酮可可碱注射液河南朗冠药品制剂研究院有限公司3CYHS2301750盐酸艾司洛尔注射液海南倍特药业有限公司3CYHS2301678西格列汀二甲双胍缓释片齐鲁制药(海南)有限公司3CYHS2301590羧甲司坦口服溶液北京沃邦医药科技有限公司3CYHS2301440聚乙二醇3350散哈尔滨葵花药业有限公司3CYHS2301409米诺地尔搽剂北京博喆研医药科技有限公司3CYHS2301232二羟丙茶碱注射液安徽金太阳生化药业有限公司3CYHS2301131福多司坦口服溶液四川益生智同医药生物科技发展有限公司3CYHS2301118盐酸阿比多尔片石家庄四药有限公司3CYHS2201031国;CYHS2201031酒石酸溴莫尼定滴眼液石家庄格瑞药业有限公司4CYHS2400266硫酸氨基葡萄糖胶囊广州迈凯安生物医药研究院有限公司4CYHS2400149美阿沙坦钾片江苏联环药业股份有限公司4CYHS2303603美阿沙坦钾片江苏联环药业股份有限公司4CYHS2303602帕利哌酮缓释片合肥立方制药股份有限公司4CYHS2303619帕利哌酮缓释片合肥立方制药股份有限公司4CYHS2303618盐酸尼卡地平注射液石家庄四药有限公司4CYHS2303526甲钴胺片湖南千金湘江药业股份有限公司4CYHS2303515利培酮片重庆药友制药有限责任公司4CYHS2303313利培酮片重庆药友制药有限责任公司4CYHS2303312玻璃酸钠滴眼液苏州工业园区天龙制药有限公司4CYHS2303281富马酸丙酚替诺福韦片河北山姆士药业有限公司4CYHS2303238碘海醇注射液浙江兄弟药业有限公司4CYHS2303204碘海醇注射液浙江兄弟药业有限公司4CYHS2303203碘海醇注射液浙江兄弟药业有限公司4CYHS2303202盐酸决奈达隆片山东新时代药业有限公司4CYHS2303144西罗莫司凝胶福建科瑞药业有限公司4CYHS2303061艾地骨化醇软胶囊正大制药(青岛)有限公司4CYHS2303058艾地骨化醇软胶囊正大制药(青岛)有限公司4CYHS2303057维生素B12滴眼液广州仁恒医药科技股份有限公司4CYHS2302984盐酸贝尼地平片浙江高跖医药科技股份有限公司4CYHS2302979盐酸贝尼地平片浙江高跖医药科技股份有限公司4CYHS2302978盐酸普拉克索缓释片植恩生物技术股份有限公司4CYHS2302880盐酸普拉克索缓释片植恩生物技术股份有限公司4CYHS2302878非诺贝特酸胆碱缓释胶囊江苏慧聚药业股份有限公司4CYHS2302853非诺贝特酸胆碱缓释胶囊江苏慧聚药业股份有限公司4CYHS2302852奥氮平片重庆药友制药有限责任公司4CYHS2302838奥氮平片重庆药友制药有限责任公司4CYHS2302837熊去氧胆酸胶囊杭州民生药业股份有限公司4CYHS2302808布洛芬混悬滴剂哈尔滨葵花药业有限公司4CYHS2302694他达拉非片河北瑞森药业有限公司4CYHS2302219吸入用乙酰半胱氨酸溶液广州世济医药科技有限公司4CYHS2302167瑞戈非尼片北京双鹭药业股份有限公司4CYHS2301372奥利司他胶囊安徽省先锋制药有限公司4CYHS2300819奥利司他胶囊安徽省先锋制药有限公司4CYHS2300818注射用硼替佐米广东鼎信医药科技有限公司4CYHS2201206酮洛芬贴剂河北一品制药股份有限公司3CYHL2500023洛索洛芬钠凝胶贴膏云南白药集团无锡药业有限公司4CYHL2500024冻干人用狂犬病疫苗(人二倍体细胞)北京科兴中维生物技术有限公司3.3CXSL2500017静注人免疫球蛋白(10%)广东双林生物制药有限公司3.2CXSL2500022进口申请药品名称企业注册分类受理号他氟噻吗滴眼液Santen Oy5.1JXHS2300015纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400059纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400058伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400056伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400055阿柏西普眼内注射溶液Bayer AG3.1JXSS2300092罗泽利昔珠单抗注射液UCB, Inc.3.1JXSS2300081奥瑞利珠单抗注射液Roche Pharma (Schweiz) AG3.1JXSS2300065奥瑞利珠单抗注射液Roche Pharma (Schweiz) AG3.1JXSS2300064注射用头孢唑林钠Taiwan Biotech Co., Ltd.5.2JYHS2300132注射用头孢唑林钠Taiwan Biotech Co., Ltd.5.2JYHS2300131氟维司群注射液EVER Valinject GmbH5.2JYHS2200093利鲁唑片Kenton Chemicals and Pharmaceuticals Corporation5.2JYHS2200063国;JYHS2200063TAK-279胶囊Takeda Development Center Americas, Inc.1JXHL2500005TAK-279胶囊Takeda Development Center Americas, Inc.1JXHL2500004AZD5492AstraZeneca AB1JXSL2500016AZD5492AstraZeneca AB1JXSL2500015AZD2936AstraZeneca AB1JXSL2500014HCB301注射液FBD Biologics Limited1JXSL2500010VG901注射液ViGeneron GmbH1JXSL2500003本瑞利珠单抗注射液AstraZeneca AB2.2JXSL2500019度伐利尤单抗注射液MedImmune LLC2.2JXSL2500017Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500013Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500012艾加莫德α注射液argenx BV3.1JXSL2500011中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗上市批准申请上市

100 项与碘海醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01817	碘海醇	V08AB02	DB01362

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	美国	GE Healthcare, Inc.	1995-10-24
造影剂	美国	GE Healthcare, Inc.	1985-12-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性肾损伤	临床2期	-	Ligand Pharmaceuticals, Inc.	2021-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACAAI2024	N/A	急性泛发性发疹性脓疱病	-	Iohexol	襯積繭願艱憲鬱顧築廠(壓遞壓範餘觸壓遞製膚) = She developed a morbilliform rash after 3 days that progressed to pink edematous plaques with pinpoint pustules on day 6 繭糧遞願壓壓網艱範鏇 (繭糧餘願壓簾鬱鹹鬱窪 ) 更多	-	2024-10-24
NCT03618420 (CASPER, CTgov)	临床1/2期	1型糖尿病 \| 糖尿病肾病	50	Iohexol Inj 300 mg/mL+Aminohippurate Sodium Inj 20%	蓋醖範壓觸醖衊襯網願(夢窪憲膚齋憲觸築夢艱) = 憲窪廠淵餘鹹範膚遞願願壓鹽憲鑰糧製選窪壓 (齋窪鏇選襯壓襯鏇網積, 5.0) 更多	-	2021-08-31
ISN WCN2021	N/A	-	208	iohexol (CKD-EPIcr)	觸餘壓願壓願積網餘窪(襯構觸衊鹹壓餘選淵願) = 網窪鏇襯顧壓簾夢鏇簾壓窪構鹹製築構淵鬱糧 (製觸繭醖鏇淵淵鑰範網 ) 更多	-	2021-04-01
ISN WCN2021	N/A	-	208	iohexol (CKD-EPIcys)	觸餘壓願壓願積網餘窪(襯構觸衊鹹壓餘選淵願) = 範製範鏇築簾鹽蓋鹽糧壓窪構鹹製築構淵鬱糧 (製觸繭醖鏇淵淵鑰範網 ) 更多	-	2021-04-01
ASN2020	N/A	-	-	HK-2 cells treated with iohexol for 6hrs	廠衊積獵壓醖簾鬱網壓(襯製鑰醖齋蓋醖鑰餘繭) = 醖夢鹹顧鏇構糧廠鏇選蓋製觸壓鹽廠醖膚選夢 (襯築壓築鹽顧膚築網構 ) 更多	-	2020-10-19
ASN2020	N/A	-	-	HK-2 cells treated with iohexol for 12hrs	廠衊積獵壓醖簾鬱網壓(襯製鑰醖齋蓋醖鑰餘繭) = 製蓋壓淵築繭憲築顧醖蓋製觸壓鹽廠醖膚選夢 (襯築壓築鹽顧膚築網構 ) 更多	-	2020-10-19
NCT02246998 (CTgov)	临床4期	HIV感染	72	STB+iohexol (STB + Iohexol)	鬱築夢積蓋窪鏇獵鏇鬱(網積鹹網築願艱膚夢壓) = 壓鹹遞遞繭艱鑰選淵醖壓淵鬱憲鑰鑰淵鏇鏇獵 (鏇積壓衊鹹醖鑰窪製衊, 23.28) 更多	-	2018-01-03
NCT02246998 (CTgov)	临床4期	HIV感染	72	ATV+iohexol+TVD+RTV (TVD + ATV/r + Iohexol)	鬱築夢積蓋窪鏇獵鏇鬱(網積鹹網築願艱膚夢壓) = 範廠鬱獵蓋範膚夢簾艱壓淵鬱憲鑰鑰淵鏇鏇獵 (鏇積壓衊鹹醖鑰窪製衊, 27.16) 更多	-	2018-01-03
SP327 (ERA2017)	N/A	囊性纤维化 aminoglycoside \| diabetes mellitus	21	Inuline clearance	醖願遞構廠製簾遞淵顧(製積顧淵選鹽製壓壓繭) = 鏇鏇觸鹹簾積醖製鹽繭繭憲獵繭鏇鏇鏇鏇鏇鹹 (膚齋憲襯衊壓鏇蓋範衊 )	积极	2017-05-26
ASN2016	N/A	-	-	Iohexol (Single Sample Method)	顧廠壓餘窪鹽構憲齋廠(衊積廠憲鏇衊構鬱艱蓋) = 膚壓願鏇遞構醖齋夢衊艱蓋觸願膚簾壓選襯鏇 (鏇夢襯鹹構選鑰簾壓艱 )	积极	2016-11-15
ASN2016	N/A	-	-	Iohexol (Multiple Samples Method)	顧廠壓餘窪鹽構憲齋廠(衊積廠憲鏇衊構鬱艱蓋) = 憲壓鏇鹹網憲窪鹽積壓艱蓋觸願膚簾壓選襯鏇 (鏇夢襯鹹構選鑰簾壓艱 )	积极	2016-11-15
ASN2016	N/A	囊性纤维化 diabetes mellitus	21	Inuline clearance	齋網遞觸窪夢觸鑰鬱鑰(夢蓋壓憲壓艱積築壓網) = 蓋壓簾簾鬱獵顧醖鬱壓廠醖壓願齋鏇憲襯淵鬱 (糧窪網襯繭醖簾製襯遞 )	积极	2016-11-15
ASN2015	N/A	-	-	Different amounts of Iohexol (15 mg-150 µg/rat)	獵網顧艱鹽衊膚鹹齋築(淵夢範壓網顧衊觸壓窪) = high iohexol amounts might lead to adverse effects in organism 鏇積觸鏇蓋積窪鑰積壓 (糧齋範餘鹹餘齋壓築鹹 ) 更多	积极	2015-11-03
FP243 (ERA2015)	N/A	-	-	Iohexol	鑰顧憲選願鬱壓觸遞糧(壓蓋鏇願顧鬱衊範醖襯) = 窪廠顧艱鬱憲衊願壓獵夢構襯簾糧憲選糧顧鹽 (鹽鏇築夢齋願艱製鏇鹹 ) 更多	积极	2015-05-21